Kim Dong-Yeon, Cho Sang-Geon, Bom Hee-Seung
Department of Nuclear Medicine, Chonnam National University Medical School and Hwasun Hospital, 322 Seoyang-ro Hwasun-eup, Hwasun-gun, Jeollanam-do 58128 Republic of Korea.
Nucl Med Mol Imaging. 2018 Aug;52(4):266-278. doi: 10.1007/s13139-018-0521-1. Epub 2018 May 8.
Myocardial perfusion imaging using positron emission tomography (PET) has several advantages over single photon emission computed tomography (SPECT). The recent advances in SPECT technology have shown promise, but there is still a large need for PET in the clinical management of coronary artery disease (CAD). Especially, absolute quantification of myocardial blood flow (MBF) using PET is extremely important. In spite of considerable advances in the diagnosis of CAD, novel PET radiopharmaceuticals remain necessary for the diagnosis of CAD because clinical use of current cardiac radiotracers is limited by their physical characteristics, such as decay mode, emission energy, and half-life. Thus, the use of a radioisotope that has proper characteristics and a proper half-life to develop myocardial perfusion agents could overcome these limitations. In this review, the current state of cardiac PET and a general overview of novel F or Ga-labeled radiotracers, including their radiosynthesis, in vivo characterization, and evaluation, are provided. The future perspectives are discussed in terms of their potential usefulness based on new image analysis methods and hybrid imaging.
与单光子发射计算机断层扫描（SPECT）相比，使用正电子发射断层扫描（PET）进行心肌灌注成像具有多个优势。SPECT技术的最新进展已显示出前景，但在冠状动脉疾病（CAD）的临床管理中，对PET仍有很大需求。特别是，使用PET对心肌血流量（MBF）进行绝对定量极为重要。尽管CAD诊断取得了显著进展，但新型PET放射性药物对于CAD诊断仍然是必要的，因为当前心脏放射性示踪剂的临床应用受到其物理特性（如衰变模式、发射能量和半衰期）的限制。因此，使用具有适当特性和半衰期的放射性同位素来开发心肌灌注剂可以克服这些限制。在本综述中，提供了心脏PET的当前状态以及新型F或Ga标记放射性示踪剂的概述，包括它们的放射性合成、体内表征和评估。基于新的图像分析方法和混合成像，从其潜在用途方面讨论了未来展望。
